The department has a strong history of extramural funding, especially in the areas of schizophrenia, depression, brain stimulation, and suicide. We have received about $2,000,000 in direct costs support for our extramural research programs since fiscal year 2013, with the strongest support coming from the NIMH.
Active Extramural Grants in the Department, by topic:
Schizophrenia
A phase 3 study to evaluate weight gain of ALKS 3831 compared to Olanzapine in adults
with schizophrenia
Alermes, Inc
PI: Joseph McEvoy, M.D.
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess
the efficacy, safety and tolerability of AVP-786 (deuterated [d6] dextromethorphan
hydrobromide [d6-DM]/duinidine sulfate [Q]) as an adjunctive treatment for patients
with residual schizophrenia.
Avanir Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
NARSAD Independent Investigator Grant
PI: Brian Miller, M.D., Ph.D., MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
Stanley Medical Research Institute
PI: Brian Miller, M.D., Ph.D., MPH
A potential state and relapse predictive marker in schizophrenia.
National Institute of Mental Health
PI: Brian Miller, M.D., Ph.D., MPH
BDNF/TrkB: a possible therapeutic target for schizophrenia.
National Institute of Mental Health
PI: Anilkumar Pillai, Ph.D
Paliperidone, mimicking paliperidone palmitate administration on brain BDNF: implications
for relapse and neuroplasticity in schizophrenia.
Ortho Mc-Neil Janssen Pharma
PI: Anilkumar Pillai, Ph.D
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy,
safety, and tolerability of orally administered BI 409306 during a 52-week treatment
period as an early intervention in patients with attenuated psychosis syndrome.
Boehringer Ingelheim Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, M.D.
Metformin and Lorcaserin for weight loss in people with schizophrenia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PI: Joseph McEvoy, M.D.
A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study
to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose
levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms
of schizophrenia
Millennium Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
with schizophrenia
Biogen MA, Inc.
PI: Joseph McEvoy, M.D.
Mood Disorders, Suicide and Sleep
Investigation of the Relationship between suicidal ideation and dysfunctional beliefs
about sleep.
PI: W. Vaughn McCall, M.D.
Rest-IT: Reducing suicidal ideation through treatment of insomnia.
National Institute of Mental Health
PI: W. Vaughn McCall, M.D.
Rest-IT: Reducing suicidal Ideation through treatment of nightmares.
The American Foundation for Suicide Prevention
PI: W. Vaughn McCall, M.D.
Regulation of TrkB signaling by 5-HT: role of transglutaminase 2
National Institute of Mental Health
PI: Anilkumar Pillai, Ph.D
Glucocorticoid-induced TrkB receptor regulation by ubiquitination
National Institute of Mental Health
PI: Anilkumar Pillai, Ph.D
Pilot studies of pupillometry in suicidal and non-suicidal patients
Augusta University
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Reducing suicide ideation through insomnia treatment (REST-IT)
NIH/NIMH
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Reducing suicidal ideation through treatment of nightmares - PTSD (REST-ON)
American Foundation of Suicide Prevention
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Bipolar Disorder
5/5 Bipolar-Schizophrenia Network for intermediate phenotypes
National Institute of Mental Health
PI: Peter F. Buckley, M.D., Dean, Medical College of Georgia
Brain stimulation: ECT and rTMS
A randomized double-blind feasibility study comparing mood and cognitive outcomes
for depressed patients treated with transcranial magnetic stimulation (TMS) combined
with Lumosity cognitive exercises vs. computer game control task.
PI: Peter B. Rosenquist, M.D.
The use of paired pulse TMS measures to assess drug effects on Neuronal Excitability
in Amyotrophic Lateral Sclerosis.
PI: Peter B. Rosenquist, M.D.
Focal Electrically-Administered Seizure Therapy (FEAST): A preliminary study.
MECTA Corporation
PI: Peter B. Rosenquist, M.D. and W. Vaughn McCall, M.D.
Low pulse amplitude focal ECT for treatment-resistant depression
ClinicalTrials.gov Identifier: NCT02583490
PI: Nagy Youssef, M.D.
Focal Electrically-Administered Seizure Therapy (FEAST) (2-site study)
Mecta Corporation (ClinicalTrials.gov Identifier: NCT02535572)
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Magnetic seizure therapy compared to ECT in major depressive disorder: A medication-free
clinical controlled trial
Tanta University, Egypt
Consultant/Co-mentor: Nagy Youssef, M.D.
Augmentation versus Switch: Comparative effectiveness research trial for antidepressant
incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD)
Patient-Centered Outcomes Research Institute (PCOI)
ClinicalTrials.gov (Identifier: NCT02977299)
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youseff, M.D.
Other
Novel statistical approaches to analyzing actigraphy data.
PI: W. Vaughn McCall, M.D.
A randomized, double-blind, placebo-controlled, fixed dose study of SD-809 (deutetrabenazine)
for treatment of moderate to severe tardive dyskinesia.
Auspex Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
An open label, long-term safety study of SD-809 (deutetrabenazine) for treatment of
moderate to severe tardive dyskinesia.
Auspex Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
Assessment and outcomes monitoring in psychiatric clinical practice.
PI: Peter B. Rosenquist, M.D.
Screening for clozapine-induced myocarditis-A natrualistic observation study.
PI: Sandarsh Surya, MBBS and Joseph McEvoy, M.D.
A study of inner conflict and psychological well-being in Veterans with PTSD symptoms
ABRC Foundation
PI: Nagy Youssef, M.D.
Assessing medical students knowledge in diagnosis and initial treatment of depression
MCG Academic Affairs
PI: Nagy Youssef, M.D.
Role of skeletal muscle health on poor lifestyle related type 2 diabetes and cardiovascular
disease risk
NIH/NIDDK
Multiple educational grant from Medical Scholar Program for mentorship/education
Consultant: Nagy Youssef, M.D.
Double-blind, Placebo-controlled, Phase 2 trial to test efficacy and safety of AV-1-1
(L-4-chlorokynurenine) as adjunct to current antidepressant therapy in patients with
major depressive disorder (MDD) with an inadequate response to current antidepressants
VistaGen Therapeutics, Inc.
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Georgia Recovery-Based Educational Approach to Treatment Project (Project GREAT)
Internally, and submitted to HRSA
PI: P. Alex Mabe, M.D.
Consultant: Nagy Youssef, M.D.
The effects of a ketogenic diet in veterans with PTSD and TBI
Pilot Study Research Program, Augusta University
Co-Investigator: Nagy Youssef, M.D.
GRISAT Educational Grant (GRU Interprofessional Substance Abuse Training for Health
Professions (GRISAT)
SAMHSA
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
A six-week, randomized, double-blind, placebo-controlled, suvorexant augmentation
study of antidepressant treatment of major depressive disorder with residual insomnia
Merck & Co., Inc/Institute for Advanvced Medical Research
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
A phase IV, double-blind, placebo-controlled, randomized withdrawal study to evaluate
the persistence of effect and safety of Valbenazine for the treatment of Tardive Dyskinesia
Neurocrine Biosciences, Inc.
PI: Joseph McEvoy, M.D.
